Results 61 to 70 of about 1,055,543 (397)
, 2004 Apolipoprotein M (apoM) is a 26-kDa protein that is mainly associated with high-density lipoprotein (HDL) in human plasma, with a small proportion present in triglyceride-rich lipoproteins (TGRLP) and low-density lipoproteins (LDL).
Luo, Guanghua +3 more
core +3 more sources
Molecular Oncology, EarlyView.In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim +11 more
wiley +1 more source
Journal of Lipid Research, 2013 Platelet-activating factor (PAF), 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, is a potent phospholipid mediator and has been reported to be localized in atherosclerotic plaque.
Yun H. Kim +8 more
doaj +1 more source
The release of platelet-activating factor from human endothelial cells in culture.
Journal of Immunology, 1983 The release of platelet-activating factor (PAF) from stimulated human endothelial cells (HEC) cultured from normal term, umbilical cord veins is described.
G. Camussi +6 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Small extracellular vesicles are a promising source of diagnostic molecules. We conducted a comprehensive study, including transcriptome profiling and RT‐qPCR validation on large cohorts of samples. Diagnostic panels enabling sensitive detection of colorectal cancer and precancerous lesions were established. Some molecules were differentially expressed
Petra Vychytilova‐Faltejskova +26 more
wiley +1 more source
Platelet activating factor revisited [PDF]
Thorax, 1997 8A2 and acetyltransferase on membrane alkylacyl phospholipids. PAF was found to possess many properties that made it well suited as a proinflammatory mediator of inflammation in many inflammatory diseases. 1 Interest in Degradation of PAF its potential role as a mediator of asthma was fuelled Being a potent bioactive mediator, it makes sense that PAF ...
openaire +3 more sources
Journal of Immunology, 1979 Platelet activating factor (PAF) released in vivo into the plasmas of rabbits during development of IgE-induced systemic anaphylactic shock had indistinguishable physicochemical and functional properties when compared with PAF released in vitro from ...
R. Neal Pinckard +2 more
semanticscholar +1 more source
Non-canonical proteolytic activation of human prothrombin by subtilisin from Bacillus subtilis may shift the procoagulant\ue2\u80\u93anticoagulant equilibrium toward thrombosis [PDF]
, 2017 Blood coagulation is a finely regulated physiological process culminating with the factor Xa (FXa)-mediated conversion of the prothrombin (ProT) zymogen to active -thrombin (T).
Acquasaliente, Laura +5 more
core +1 more source
Molecular Oncology, EarlyView.Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
Effects of Platelet-Activating Factor on Brain Microvascular Endothelial Cells. [PDF]
, 2018 Platelet-activating factor (PAF) is a potent phospholipid mediator that exerts various pathophysiological effects by interacting with a G protein-coupled receptor.
Abood, Mary E. +4 more
core +1 more source